Next 10 |
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection Canada NewsWire The Letter of Intent is an important ste...
2024-05-15 12:22:59 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation Takeda Pharmaceutical: Eohilia's FDA Approv...
2024-05-14 09:41:52 ET More on Scilex, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation Takeda Pharmaceutical: Eohili...
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. Takeda’s presentations will spa...
2024-05-13 09:52:52 ET More on AC Immune Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune Financial information for AC Immune Read the full article on Seeking Alpha For further details see: AC Immune rockets ...
− Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression − AC Immune to receive upfront payment of $100 million upon closing and be eligible...
2024-05-10 01:27:10 ET Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Conference Call May 09, 2024 6:00 AM ET Company Participants Christopher O’Reilly – Head-Investor Relations Christophe Weber – President and Chief Execut...
2024-05-09 08:29:13 ET More on Takeda Pharmaceutical Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits New house bill to extend COVID-era telehealth flexibilities Brist...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-05-09 06:31:11 ET Japanese pharmaceutical titan Takeda (NYSE: TAK/TSE: 4502) today announced their financial results for Q4 and the full fiscal year of 2023. The company described it in a press release as “a year of significant loss-of-exclusivity impact”, a g...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection Canada NewsWire The Letter of Intent is an important ste...
Wednesday, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine received World Health Organization’s (WHO) preq...
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. Takeda’s presentations will spa...